Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Atrial Fibrillation and Its Complications: Preventive Strategies and Relative Evidence
share announcement

Atrial Fibrillation and Its Complications: Preventive Strategies and Relative Evidence

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".

Deadline for manuscript submissions: 30 October 2024 | Viewed by 67

Special Issue Editor

Dr. Roberto Galea

E-Mail Website
Guest Editor
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland
Interests: atrial fibrillation; structural heart intervention; stroke; left atrial appendage; cardiac computed tomography angiography

Special Issue Information

Dear Colleagues,

Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, with a rising incidence and prevalence globally. AF represents an increasing healthcare issue due to the multiple potential associated complications, including a 5-fold increase in stroke and heart failure and 2-fold increase in myocardial infarction, as well as dementia and cognitive decline. Over the past decade, several therapeutic strategies have emerged in clinical practice, with the aim of preventing such complications. Oral anticoagulation reduces the risk of ischemic stroke by almost 70% but is associated with bleeding risk. Percutaneous left atrial appendage closure is a valuable alternative therapeutic strategy for stroke prevention in patients with AF at an increased risk of bleeding. Anti-arrhythmic drugs and catheter ablation are effective in reducing the AF burden and improving patients’ quality of life.

We are pleased to invite you to submit original research papers or state-of-the-art reviews for consideration for this Special Issue focusing on preventive strategies for AF and its complications, emphasizing both the supporting evidence and limitations related to current pharmacological and interventional approaches.

We look forward to receiving your contributions.

Dr. Roberto Galea
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • atrial fibrillation
  • catheter ablation
  • oral anticoagulation
  • left atrial appendage closure
  • stroke prevention

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

8 pages, 1698 KiB  
Opinion
Subclinical Atrial Fibrillation: To Anticoagulate or Not?
by Sharath Kommu and Param P. Sharma
J. Clin. Med. 2024, 13(11), 3236; https://doi.org/10.3390/jcm13113236 - 30 May 2024
Abstract
Atrial fibrillation (AF) carries a stroke risk, often necessitating anticoagulation, especially in patients with risk factors. With the advent of implantable and wearable heart monitors, episodes of short bouts of atrial arrhythmias called atrial high-rate episodes (AHREs) or subclinical AF (SCAF) are commonly [...] Read more.
Atrial fibrillation (AF) carries a stroke risk, often necessitating anticoagulation, especially in patients with risk factors. With the advent of implantable and wearable heart monitors, episodes of short bouts of atrial arrhythmias called atrial high-rate episodes (AHREs) or subclinical AF (SCAF) are commonly identified. The necessity of anticoagulation in patients with SCAF is unclear. However, recent randomized controlled trials, the NOAH-AFNET 6 and ARTESIA, have offered insights into this matter. Furthermore, a study-level meta-analysis combining data from both these trials has provided more detailed information. Reviewing the information thus far, we can conclude that DOACs can result in a notable reduction in the risk of ischemic stroke and can potentially decrease the risk of debilitating stroke, albeit with an increased risk of major bleeding. Thus, informed, shared decision-making is essential, weighing the potential benefits of stroke prevention against the risk of major bleeding when considering anticoagulation in this patient population. Full article
(This article belongs to the Special Issue Atrial Fibrillation and Its Complications: Preventive Strategies and Relative Evidence)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop